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Immunoglobulins Against Tyrosine-Nitrated Epitopes in
Coronary Artery Disease
Leonor Thomson, MD, PhD; Margarita Tenopoulou, PhD; Richard Lightfoot, MS; Epida Tsika, PhD;
Ioannis Parastatidis, MD, PhD; Marissa Martinez, BS; Todd M. Greco, PhD;
Paschalis-Thomas Doulias, PhD; Yuping Wu, PhD; W.H. Wilson Tang, MD;
Stanley L. Hazen, MD, PhD; Harry Ischiropoulos, PhD
Background—Several lines of evidence support a pathophysiological role of immunity in atherosclerosis. Tyrosine-
nitrated proteins, a footprint of oxygen- and nitrogen-derived oxidants generated by cells of the immune system, are
enriched in atheromatous lesions and in circulation of patients with coronary artery disease (CAD). However, the
consequences of possible immune reactions triggered by the presence of nitrated proteins in subjects with clinically
documented atherosclerosis have not been explored.
Methods and Results—Specific immunoglobulins that recognize 3-nitrotyrosine epitopes were identified in human lesions,
as well as in circulation of patients with CAD. The levels of circulating immunoglobulins against 3-nitrotyrosine
epitopes were quantified in patients with CAD (n374) and subjects without CAD (non-CAD controls, n313). A
10-fold increase in the mean level of circulating immunoglobulins against protein-bound 3-nitrotyrosine was
documented in patients with CAD (3.751.8 g antibody Eq/mL plasma versus 0.360.8 g antibody Eq/mL plasma),
and was strongly associated with angiographic evidence of significant CAD.
Conclusions—The results of this cross-sectional study suggest that posttranslational modification of proteins via nitration
within atherosclerotic plaque-laden arteries and in circulation serve as neo-epitopes for the elaboration of immuno-
globulins, thereby providing an association between oxidant production and the activation of the immune system in 
CAD.
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Chronic inflammation, oxidative processes, and the acti-
vation of the immune system are implicated in the
pathogenesis of atherosclerosis.1–3 The detection and quanti-
fication of tyrosine-nitrated proteins in human and animal
models of atherosclerosis has provided one of the mechanistic
links between chronic inflammation and oxidative processes
in coronary artery disease (CAD). Tyrosine nitration is a
covalent posttranslational modification of proteins that arises
from the reaction of protein tyrosine residues with nitric
oxide-derived oxidants.4–6 Using mass spectrometry-based
proteomic approaches, site-specific nitration of proteins with
pathobiological relevance to CAD have been revealed,7,8
whereas quantification of 3-nitrotyrosine in plasma using
stable isotope dilution liquid chromatography tandem mass
spectrometry demonstrated its association with CAD.9
Despite the potential utility of 3-nitrotyrosine as a bio-
marker, at the individual protein level, it remains unclear
whether protein nitration is responsible for alterations in
cellular function that imparts an increased risk for disease
development or unfavorable outcomes. Emerging data
implicate tyrosine nitration as an activator of immune
responses, including the elaboration of immunoglobulins,
and in inflammatory diseases such as acute lung injury,
osteoarthritis, rheumatoid arthritis, and systemic lupus
erythematosus.10 –12 Moreover, a possible role of immune
modulation by protein nitration can be evoked in other
prevalent vascular diseases, such as angiotensin II-induced
hypertension in which oxidants, T cells, and infiltrating
monocytes contribute to the disease pathogenesis.13,14 In
this study, we provide clinical data demonstrating that
circulating immunoglobulins that recognize protein-bound
3-nitrotyrosine are increased in patient with CAD and are
associated with enhanced risk of angiographic evidence of
significant CAD.
Materials and Methods
Subjects
Stable subjects undergoing elective diagnostic cardiac evaluation
with coronary angiography were recruited prospectively to partici-
pate. All blood draws were from fasting subjects, venous sampling
into EDTA (lavender top) Vacutainers prior to heparin administra-
tion from sequential consenting subjects at the time of cardiac
catheterization. Blood was placed immediately either on ice or in a
refrigerator, and centrifuged subsequently for 15 minutes at 10 000 g
at 4°C. Plasma was maintained between 0°C and 4°C, and aliquots
were frozen at 80°C within 2 hours of blood draw. Subjects who
experienced acute coronary syndrome within 30 days of sample
collection or had significant end-organ dysfunction were excluded.
All subjects included in the current studies were confirmed to be
troponin I (Abbott Architect assay) negative. Angiographic evidence
of significant CAD was defined by the presence of at least 50%
stenosis in one or more major coronary vessel as judged by at least
2 cardiologists blinded to patient identification and history. The
demographic data for the subjects are reported in Table 1. Subjects
with no history of CAD, significant angiographic (using 50%
stenosis as the cutoff) evidence of cardiovascular disease, peripheral
artery disease, or other significant end-organ dysfunction were
considered non-CAD subjects. The reasons for cardiac catheteriza-
tion in the study cohort (subjects can have 1 or more reasons)
included history of positive or indeterminate stress test (46%),
evaluation for possible ischemic causes of symptoms (69%), preop-
erative evaluation (14%), and history of cardiomyopathy (3%). All
study participants gave informed consent, and the study was ap-
proved by the Cleveland Clinic Institutional Review Board.
Materials
Free 3-nitrotyrosine and the synthetic octapeptide containing 2
3-nitrotyrosine residues (CGnitroYGGGnitroYG) (CPC Scientific,
San Jose, CA) were conjugated to horseradish peroxidase (HRP)
following a previously published 1-step procedure.10 Affinity-
purified polyclonal antinitrotyrosine antibodies were generated and
characterized extensively,8,15,16 and used as reference immunoglob-
ulin. Synthetic peptides comprising amino acids 213 to 219 of human
apolipoprotein A-I sequence (213LAEYHAK219) with either tyrosine
in position 216 or 3-nitrotyrosine (213LAEnitroYHAK219) were used
for ligand competition. Human fibrinogen (America Diagnostica,
Stamford, CT), fibronectin, and ceruloplasmin were nitrated by
adding 3 consecutive bolus additions of peroxynitrite (final concen-
tration, 100 mol/L) in 0.1 mol/L phosphate buffer containing
100 mol/L diethylene triamine pentaacetic acid and 25 mmol/L
bicarbonate, pH 7.2. These proteins were nitrated chemically and
used to screen for the circulating immunoglobulin isotype.
Immunohistochemistry
To probe for tyrosine-nitrated proteins, sections from human carotid
atheromatous lesions were fixed in cold methanol–acetone solution
for 20 minutes at 20°C. Staining for tyrosine-nitrated proteins was
performed using rabbit polyclonal affinity-purified antinitrotyrosine
antibodies (7 g/mL) raised against the synthetic peptide described
previously.15,16 A goat antirabbit secondary antibody conjugated to
HRP (Biorad, Hercules, CA) was used for signal detection. As
control for the specificity of the antibody binding, the anti-3-
nitrotyrosine antibody was preincubated with 250 mol/L
3-nitrotyrosine octapeptide or with 250 mol/L of the corresponding
tyrosine octapeptide for 1 hour at room temperature. Other control
experiments included preincubation with 2.5 mmol/L free
3-nitrotyrosine, reduction of tissue nitrotyrosine to aminotyrosine
using 0.5 mol/L dithionite in 0.1 N sodium hydroxide for 20 minutes
at room temperature, as well as omission of the primary antibody. Oil
Table 1. Baseline Subject Characteristics by Coronary Artery Disease Status
Characteristic
All Subjects
(n687)
Non-CAD Subjects
(n313)
Subjects With
CAD (n374) P
Demographics and cardiovascular risk factors
Age (y) 6810 618 709 0.001
Male (%) 67 37 81 0.001
Diabetes mellitus (%) 37 17 46 0.001
Hypertension (%) 73 56 80 0.001
Smoker (former/current, %) 67 52 73 0.001
Prior myocardial infarction (%) 32 0 48 0.001
Laboratory data
LDL cholesterol (mg/dL) 96 (79–119) 110 (90–130) 91 (76–112) 0.001
HDL cholesterol (mg/dL) 35 (28–41) 39 (34–50) 32 (27–39) 0.001
Triglycerides (mg/dL) 115 (86–159) 104 (79–143) 119 (90–169) 0.006
Total leukocyte count (WBC/hpf) 6.12 (5.11–7.37) 5.87 (4.61–6.95) 6.24 (5.21–7.57) 0.003
Uric acid (mg/dL) 6.3 (5.1–7.3) 5.6 (4.7–6.7) 6.6 (5.5–7.6) 0.003
hsCRP (mg/L) 2.53 (1.07–6.66) 1.94 (0.85–5.29) 2.83 (1.24–7.08) 0.004
Myeloperoxidase (pg/mL) 114 (74–246) 104 (70–167) 124 (80–286) 0.001
Creatinine clearance (mL/min per 1.73 m) 88 (66–110) 97 (83–122) 79 (62–106) 0.001
Baseline medications
Aspirin 74 60 81 0.001
-adrenergic blockers 58 47 62 0.002
Angiotensin-converting enzyme inhibitors 53 34 61 0.001
Statin therapy 54 26 67 0.001
Values expressed in meanstandard deviation or median (interquartile range). LDL indicates low-density lipoprotein; HDL,
high-density lipoprotein; WBC/hpf, white blood cells per high power field; and hsCRP, high-sensitivity C-reactive protein.
red-O, trichrome staining, and 3,3-diaminobenzidine-chromogenic
detection of immunoglobulins was performed in human lesions fixed
in 4% paraformaldehyde as described previously.8,15,16
Affinity Purification of Immunoglobulins
Proteins that bind to 3-nitrotyrosine were affinity isolated using an
Amino Link Plus Immobilization Kit (Pierce Biotechnology, Inc,
Rockford, IL), as described previously with minor modifications.8
Briefly, 10 mg plasma proteins (combining plasma from 3 patients
with CAD) were diluted in binding buffer (50 mmol/L potassium
phosphate, 400 mmol/L NaCl, pH 7.5), applied to the column, and
incubated for 1 hour at room temperature. Unbound protein fractions
were eluted by centrifugation with binding buffer. Bound proteins
were eluted with 0.1 mol/L citrate, pH 2.5, and neutralized with 1
mol/L Tris, pH 9. Bound fractions were concentrated and buffer
exchanged using Millipore 10-kDa centrifugal filter units (Millipore
Corporation, Billerica, MA). The protein fractions were separated on
10% SDS-PAGE and transferred to Immobilon-P polyvinylidene
difluoride membranes (Millipore Corporation, Bedford, MA), at 100
V and 4°C. After blocking with 3% BSA in Tris buffered saline with
0.05% tween-20, the membranes were incubated with either goat
antihuman immunoglobulin G (IgG)-IRDye 800 CW (Rockland
Immunochemicals, Inc, Boyertown, PA) or mouse antihuman IgM
(1:2500; Sigma, St. Louis, MO) plus goat antimouse IgG conjugated
to Alexa Fluor 680 (1:5000; Invitrogen, Eugene, OR) in blocking
buffer. Images were obtained with an Odyssey near-infrared imaging
system (LI-COR, Inc, Lincoln, NE) at 700 nm and 800 nm.
Human arterial tissue was obtained from the National Disease
Resource Institute (Philadelphia, PA) or the Cleveland Clinic.
Tissues (approximately 1 g) were cleaned of connective tissue and
blood, snap-frozen in liquid nitrogen, and pulverized in the frozen
state and stored at 80°C until use. Frozen tissue powder was
thawed in 5 mL extraction buffer containing a protease inhibitor
cocktail (Sigma, St. Louis, MO), and macerated further with a
Tissue-Tek (Cincinnati, OH) homogenizer operated on full power for
10 s. This procedure was repeated 4 times per tissue sample. Tissue
extracts were centrifuged at 700 g for 5 minutes and 21 000 g twice
for 10 minutes to remove particulate material. Supernatants were
combined and loaded to appropriate columns for affinity enrichment.
Isotype Determination
ELISA methodologies were developed to determine the isotype and
the subisotype of the circulating immunoglobulin that recognize
protein-bound 3-nitrotyrosine. First, to differentiate between IgG and
IgM, 100 L of 10 g/mL of the synthetic 3-nitrotyrosine octapep-
tide described earlier was diluted in 50 mmol/L bicarbonate buffer,
pH 9, and added in the wells of 96 well plates (MAXI-SORP, Nunc,
Roskilde, Denmark). After overnight incubation at 4°C, the plates
were washed and incubated in the presence of 100 L/well 3% BSA
in Tris buffered saline with 0.05% tween-20 (working buffer) for 2
hours at room temperature. Human plasma from patients with CAD
(5 mg plasma protein/mL) were added to each well and incubated for
2 hours at room temperature. Antihuman IgG and antihuman IgM
HRP-conjugated antibodies (Sigma) diluted to 1:5000 in working
buffer were added to appropriate series of wells. Peroxidase activity
bound to each well was determined with 3,3,5,5 tetramethylbenzi-
dine (Pierce) substrate.
To determine the IgG subclass of the antibody, microplates were
coated with 100 L of 5 g/mL solution of nitrated and native
ceruloplasmin, fibronectin, and fibrinogen. The plates were incu-
bated overnight at 4°C. After blocking, 100 L human plasma
(diluted 1:40), alone or in the presence of 10 mol/L synthetic
3-nitrotyrosine octapeptide (specificity control) in blocking buffer,
was added to each well and incubated for 1 hour, followed by the
addition of 100 L/well 1:2000 dilutions of monoclonal HRP-
conjugated antihuman IgG 1, 2, 3, and 4 (Sigma). Absorbance was
measured at 450 nm on a microplate reader (Spectra-Max 250;
Molecular Devices Corporation, Sunnyvale, CA). The background
absorbance obtained with unmodified proteins was subtracted from
the absorbance of the samples that reacted with the nitrated protein
antigens.
Ligand Competition ELISA
A competition ELISA described previously was implemented to
determine the levels and specificity of circulating immunoglobulins
that recognize 3-nitrotyrosine in human plasma.10 Briefly, each well
of a 96-well microtiter plate (MAXI-SORP) was coated with 50 L
of serial dilutions of human plasma (0.02–10 mg protein/mL) in
50 mmol/L sodium bicarbonate buffer, pH 9. After blocking, 75
nmol/L HRP-conjugated 3-nitrotyrosine or an HRP-conjugated syn-
thetic octapeptide containing 2 3-nitrotyrosine residues (CGni-
troYGGGnitroYG) were added in 0.1% BSA in Tris buffered saline
with 0.05% tween-20 and were incubated for 1 hour. Peroxidase
activity bound to each well was determined using the H2O2-
peroxidase-mediated oxidation of tetramethylbenzidine measuring
absorbance at 450 nm. To test the specificity of detection, the
absorbance at 450 nm was competed in each sample by including
excess free, unlabeled 3-nitrotyrosine (2.5 mmol/L). In some exper-
iments, the CGnitroYGGGnitroYG octapeptide was used as the
competitor.
A polyclonal rabbit antinitrotyrosine IgG antibody (0.08–40 g
protein/mL), characterized in detail previously,15,16 was run each day
along with plasma samples. The antibody titer in each sample was
calculated using the absorbance at 450 nm of the samples (Abs450 nm),
and the average of the parameters of the dose–response curve
obtained with the polyclonal antinitrotyrosine antibody using the
following equation:
Antibod y titer  200C ADAbs450 nmD1
1/B
where 200 represents the sample dilution, and the average values for
the parameters A, B, C, and D were 0.07, 2.21, 0.04, and 1.57,
respectively, denoting minimal absorbance, slope at the linear part of
the curve, the dose at the central point, and the maximal absorbance,
respectively. Antibody titers in human plasma are therefore ex-
pressed as microgram equivalents of the polyclonal antibody per
milliliter of plasma (g Ab Eq/mL plasma).
Isolation of Nitrated Proteins for
Mass Spectrometry
Proteins bearing the 3-nitrotyrosine epitope were affinity captured
from human CAD plasma by using the polyclonal anti-3-
nitrotyrosine antibody conjugated to a recombinant protein A col-
umn (Pierce). Pooled plasma from 6 patients with CAD (14 mg total
protein) was loaded into the column in 0.1 mol/L HEPES, pH 7.4
(binding buffer), and was incubated overnight at 4°C. The column
was washed successively with 10 mL of the following solutions:
binding buffer, 0.5 mol/L NaCl, and binding buffer again. Bound
fractions were eluted with 10 mL of 0.1 mol/L glycine, pH 2.5,
containing 0.15 mol/L NaCl. After concentration and buffer ex-
change using Centriprep YM-10 filters (Millipore Corporation,
Billerica, MA), proteins were separated on 10% SDS-PAGE, and
stained with colloidal blue (Invitrogen, Carlsbad, CA). An identical
gel was transferred to the polyvinylidene difluoride membrane for
immunodetection of protein 3-nitrotyrosine using the polyclonal
antinitrotyrosine antibody.
Gel–Liquid Chromatography Tandem Mass
Spectrometry Analysis
Colloidal blue-stained gels were cut into 112-mm slices and in-gel
digested with trypsin as described previously.8 Tryptic peptide
digests were analyzed by an LTQ linear ion trap mass spectrometer
(Thermo Electron, San Jose, CA) coupled to an Eksigent
2-dimensional liquid chromatography system (Eksigent Technolo-
gies, Livermore, CA) and autosampler. Buffers A and B were 0.1%
formic acid/1% methanol and 80% acetonitrile/0.1% formic acid/1%
methanol, respectively. Peptides were loaded isocratically onto a
C18 trap column (75 m ID25 mm; New Objective Proteopep 2
[New Objective, Inc., Woburn, MA]) at a flow rate of 1 L/min in
2% B. Peptides were then eluted onto a C18 analytic column (75 m
ID150 mm; New Objective Proteopep 2). A linear gradient was
then initiated at a flow rate of 300 nL/min for 90 minutes from 3%
to 40% B. The mass spectrometer was set to scan m/z repetitively
from 375 nm to 1600 nm followed by data-dependent tandem mass
spectrometry scans on the 5 most abundant ions with dynamic
exclusion enabled.
Generation and Evaluation of SEQUEST
Peptide Assignments
DTA files were generated from the tandem mass spectrometry
spectra extracted from RAW data files (intensity threshold, 1000;
minimum ion count, 50) and processed by the ZSA and Correction
algorithms of the SEQUEST Browser program. DTA files were
submitted to Sorcerer-SEQUEST (ver. 3.11, rev 11; Sagen Research,
San Jose, CA) using the following parameters: Database searching
was performed against a Uniprot database containing Homo sapiens
sequences from Swiss-Prot plus common contaminants, which were
then reversed and appended to the forward sequences (91 522
entries). The database was indexed with the following parameters:
mass range of 600 to 3500 atomic mass units, tryptic cleavages with
a maximum of 1 missed cleavage, and static modifications of
cysteine by carboxyamidomethylation (57 amu). The DTA files
were searched with a 2.0-amu peptide mass tolerance, 1.0-amu
fragment ion mass tolerance, and variable modification of methio-
nine (16 amu). Potential sequence-to-spectrum peptide assign-
ments generated by Sorcerer-SEQUEST were loaded into Scaffold
(version 2.2; Proteome Software, Portland, OR) to validate protein
identifications and perform manual inspection of tandem mass
spectrometry spectra containing 3-nitrotyrosine. Protein identifica-
tions were accepted at a threshold of 99% protein confidence with
2 unique peptides at 80% confidence. From these proteins,
manual inspection of 3-nitrotyrosine-containing tandem mass spec-
trometry spectra were performed using the following criteria: (1)
assignment of the majority of fragment ion abundance, (2)
3-nitrotyrosine (45 amu) modification supported by either y- or
b-ions series (5 consecutive fragments), and (3) correctly assigned
charge state and diagnostic markers, such as N-terminal proline,
C-terminal aliphatic amino acids, and loss of H2O/ammonia consis-
tent with amino acid sequence.
Statistical Analysis
The Student t test or Wilcoxon rank-sum test for continuous
variables and 2 test for categorical variables were used to examine
the difference between the groups (CAD versus non-CAD). The
relationship between plasma immunoglobulin levels and risk for
having CAD was determined by calculating the odds ratio and 95%
confidence intervals using multiple logistic regression treating im-
munoglobulin levels against protein-bound nitrotyrosine as a contin-
uous variable. Models adjusted for traditional risk factors (age,
gender, systolic blood pressure, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, smoking) or traditional risk
factors plus history of myocardial infarction, and medications (aspi-
rin, angiotensin-converting enzyme, statin, -blockers). Cubic spline
curves with 95% confidence intervals were constructed to illustrate
the relationship between antinitrotyrosine immunoglobulin levels
and the odds ratio of angiographic evidence of significant CAD. All
analyses were performed using R 2.13.1 (Foundation for Statistical
Computing, Vienna, Austria), and probability values 0.05 were
considered statistically significant.
Results
Nitrated Proteins in Human Atherosclerotic
Lesions and Plasma
The presence of nitrated proteins in atherosclerotic lesions or
plasma of patients with CAD could serve as neo-epitopes,
triggering an immune response and the elaboration of immu-
noglobulins. Therefore, we first sought to document the
presence of nitrated proteins by immunohistochemistry in
human lesions and by mass spectrometry in lesion extracts as
well as plasma of subjects with CAD.
A typical atherosclerotic lesion in human carotid artery
stained with Oil red-O is depicted in Figure 1A and 1B. The
immunofluorescence images after staining for nitrated protein
epitopes is depicted in Figure 1C through 1E, and indicate the
presence of nitrated proteins within the lesion, consistent with
previous studies in human atherosclerotic lesions.6 The specific-
ity of the antinitrotyrosine antibodies used for staining was
confirmed by competition experiments with excess of the ni-
trated octapeptide (CGnitroYGGGnitroYG) (Figure 1D). More-
over, staining with antihuman IgG also revealed the presence of
Figure 1. Immunohistochemical detection
of nitrated proteins in human atheroscle-
rotic lesions. (A and B) Oil red-O staining
of the atherosclerotic lesion in human
carotid at low magnification (1.25) (A)
and at high magnification (10) (B). (C–E)
Serial cross-sections were incubated with
polyclonal anti-3-nitrotyrosine antibody (C).
The immunoreactive nitrated proteins were
visualized in the lesions by green fluores-
cence after incubation with secondary
antirabbit/Alexa Fluor 488 antibody. Immu-
noreactivity was reduced by competition
of the primary anti-3-nitrotyrosine
antibody binding with the 250 mol/L
3-nitrotyrosine-containing octapeptide (D),
but not by 250 mol/L tyrosine-containing
octapeptide (E). Nuclei are stained blue
with 4=,-6-diamidino-2-phenylindole. The
results are representative of staining 2 dif-
ferent human lesions. (F and G) Trichrome
staining of the carotid lesion (F) immuno-
staining with antihuman immunoglobulin G
antibody revealed the presence of immu-
noglobulin G immunoglobulins within and
around the lesion (G). Immunoreactivity
(brown) was developed with 3,3-
diaminobenzidine. Bars indicate 100 m
for B through E and 1 mm for panels A, F,
and G.

3-nitrotyrosine octapeptide was used to bind the immuno-
globulins and the respective antihuman immunoglobulin to
develop, we quantified the relative levels of IgG and IgM in
the plasma of subjects with CAD. Plasma immunoglobulins
that recognize the nitrotyrosine modification were predomi-
nantly IgG, because the signal was nearly 5-fold higher for
IgG than IgM (1.40.3 and 0.30.3 average absorbance
respectively, Figure 3A). Therefore, subsequent studies fo-
cused on quantifying the levels of circulating IgG immuno-
globulin isoform in subjects. The IgG present in human
plasma of subjects with CAD was characterized further by
isotyping using an ELISA in which potential endogenous
3-nitrotyrosine-containing proteins—nitrated ceruloplasmin,
nitrated fibronectin, and nitrated fibrinogen—were used as
antigens. The predominant isotype that recognized preferen-
tially the nitrated proteins was IgG2 (Figure 3B).
ELISA Development to Quantify Plasma Levels of
Antinitrotyrosine Immunoglobulins in Subjects
With and Without CAD
We next sought to determine whether plasma immunoglobulins
that recognize the neo-epitope 3-nitrotyrosine are more prevalent
in subjects with CAD. For these studies, we modified a compe-
tition ELISA described previously for use in human plasma and
mouse models of atherosclerosis.8,10 Typical antigen–antibody
binding curves using the nitrotyrosine-containing octapeptide
conjugated to HRP are shown in Figure 3C. No binding was
observed using the same tyrosine-containing octapeptide. The
specificity of binding was confirmed by competing the binding
of the 3-nitrotyrosine peptide-conjugated HRP with excess free
3-nitrotyrosine (2.5 mmol/L), as well as unconjugated nitroty-
rosine peptide (75 mol/L). In all subsequent analyses, the
difference between the absorbance in the absence versus pres-
ence of excess 3-nitrotyrosine (2.5 mmol/L), considered as
background, was used to calculate the titer of circulating anti-3-
nitrotyrosine immunoglobulins. Furthermore, the binding of
immunoglobulins to the HRP-conjugated nitrotyrosine peptide
was competed by a peptide derived from apoA-I (213LAEnitro
YHAK219) containing 3-nitrotyrosine in place of tyrosine in
position 216. Maximal inhibition was obtained at 1 mol/L
213LAEnitroYHAK219 (Figure 3D). At the same concentration,
the unmodified apoA-I peptide, 213LAEYHAK219, was unable to
compete (Figure 3D), confirming the specificity of the immu-
noglobulins toward protein tyrosine-nitrated epitopes.
Plasma Levels of Antibodies That Recognize
Protein Nitrotyrosine Are Increased in Subjects
With CAD
Plasma levels of anti-3-nitrotyrosine immunoglobulins were
quantified in subjects with and without CAD as documented
Figure 3. Screening for circulating immunoglobulins that recognize 3-nitrotyrosine. (A) Immunoglobulin (Ig) G and IgM levels in human
plasma were measured by ELISA in the plasma of 10 randomly selected subjects with coronary artery disease using the 3-nitrotyrosine
octapeptide to bind the immunoglobulins and the respective antihuman immunoglobulin for detection. (B) IgG subclass was determined
by ELISA in 3 independent coronary artery disease plasma samples using nitrated ceruloplasmin (white bars), nitrated fibronectin
(dashed bars), and nitrated fibrinogen (gray bars) as capturing antigen, and horseradish peroxidase (HRP)-conjugated mouse antihuman
IgG1, IgG2, IgG3, and IgG4 for detection. (C) Typical antigen–antibody binding curves from 3 randomly selected subjects with coronary
artery disease each performed in triplicate using as ligand the 3-nitrotyrosine-octapeptide conjugated to HRP (F). No binding was
observed using the same tyrosine-containing octapeptide conjugated to HRP (E). The binding of the 3-nitrotyrosine octapeptide conju-
gated to HRP was eliminated with 75 mol/L unlabeled 3-nitrotyrosine-octapeptide (Œ) or by 250 mol/L 3-nitrotyrosine (f). (D) The
binding of the 3-nitrotyrosine octapeptide conjugated to HRP to 3 different plasma samples, each performed in triplicate, was also
eliminated with increasing concentrations of apolipoprotein A-I peptide 213 to 219 (213LAEnitroYHAK219), which contained
3-nitrotyrosine in position 216 (F) but not by the same peptide that contained tyrosine in position 216 (f). Data are meanstandard
deviation. CAD indicates coronary artery disease.
during elective cardiac evaluations, as described in Methods.
Subjects with clinically documented CAD had 10 times
higher levels of anti-3-nitrotyrosine immunoglobulins
(3.751.8 g Ab Eq/mL plasma) than subjects without CAD
(0.360.8 g Eq/mL plasma; P0.001 for comparison with
CAD) (Figure 4A). Interestingly, subjects with angiographic
evidence of significantly obstructed (50% stenosis) CAD
showed increased plasma anti-3-nitrotyrosine immunoglobu-
lin titers compared with subjects without CAD, regardless of
the number of coronary arteries affected by CAD (Figure 4B).
A striking dose-dependent positive association was observed
between plasma levels of antinitrotyrosine IgG and angio-
graphic evidence of significant CAD; in fact, because the
non-CAD cohort had low levels of anti-3-nitrotyrosine im-
munoglobulins (undetectable in 76% of the samples), a
remarkably large odds ratio was observed for anti-3-
nitrotyrosine IgG titer versus the presence of significant
angiographic evidence of CAD (Figure 4C). Multilogistic
regression analyses indicated that the robust association of
immunoglobulin levels against protein 3-nitrotyrosine with
cardiovascular risk remains significant even after adjustments
for multiple traditional risk factors, including age, gender,
systolic blood pressure, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, smoking, history of
myocardial infarction, and medications (aspirin, angiotensin-
converting enzyme inhibitors, statin, -blockers; Table 2).
Discussion
Clinical evidence and data from animal models have inden-
tified various forms of oxidized lipoproteins and heat shock
proteins as immunogens that induce adaptive immune re-
sponses, including antibody elaboration, and that modulate
atherosclerotic lesion formation in experimental models of
atherosclerosis.20–29 Most studies have focused predomi-
nantly on covalent adducts formed by the addition of elec-
trophilic lipid peroxidation products to proteins and their
relationship to the development and progression of athero-
sclerosis.20–26 Moreover, the levels of circulating IgM that
recognized oxidized forms of low-density lipoprotein with
covalently adducted lipid oxidation products have been re-
ported to correlate with severity of atherosclerosis in mouse
models and in some studies with the progression of athero-
sclerosis in coronary or carotid vascular beds, or with risk for
myocardial infarction and death in humans.25 Collectively,
these data highlight the critical importance of understanding
the immune system responses in CAD and raise the possibil-
ity of novel therapeutic treatments for atherosclerosis.30,31
The data also underscore the need for identifying antigens
and immune responses that are linked mechanistically to the
underlying pathophysiology of cardiovascular diseases.
Protein tyrosine nitration is considered to be a posttrans-
lational modification reflective of inflammatory-mediated
oxidative processes involving nitric oxide-derived oxidants.
Although the ability of nitrated proteins to induce the gener-
ation of specific antibodies in experimental animals has long
been known,15,16,32–36 the contribution of this posttranslational
protein modification as a trigger of immune reactions in
pathology has just recently been explored.10–12 In this study
we demonstrated for the first time the association of CAD, the
Figure 4. Antinitrotyrosine circulating immunoglobulins in coro-
nary artery disease (CAD). (A) Plasma levels of anti-3-
nitrotyrosine circulating immunoglobulins were quantified in clin-
ically documented subjects with CAD versus subjects without
significant angiographic evidence of CAD. Antibody equivalents
were calculated from standard curves performed with a poly-
clonal antinitrotyrosine antibody. (A and B) Box-whisker plots of
immunoglobulin levels encompass the 25th and 75th percen-
tiles, and lines within boxes represent median values. Bars rep-
resent the 2.5th and 97.5th percentiles. Statistically significant
differences in immunoglobulin content were found between CAD
and non-CAD (P0.0001, Kruskal-Wallis test). (C) Odds ratio
and 95% confidence interval (dotted lines) for the relationship
between plasma levels of antinitrotyrosine immunoglobulins and
angiographic evidence of significant CAD were calculated as
described under Methods. Ab indicates antibody.
most common and life-threatening cardiovascular condition,
with increased plasma levels of immunoglobulins reactive
against proteins modified by nitration. The binding of plasma
immunoglobulins to target 3-nitrotyrosine-containing bait
(HRP conjugated to 3-nitrotyrosine or 3-nitrotyrosine con-
taining octapeptide) served as a competition-based ELISA to
quantify autoantibody titers for 3-nitrotyrosine-recognizing
immunoglobulins within subjects’ plasma. The specificity of
the methodology was confirmed by numerous approaches,
including demonstration that the 3-nitrotyrosine binding ac-
tivity in plasma was outcompeted specifically by free
3-nitrotyrosine as well as by 3-nitrotyrosine-modified pep-
tides and proteins, ruling out nonspecific binding. In partic-
ular, a nitrated peptide reflecting an endogenous nitrated
tyrosine residue identified in apoA-I recovered from human
atherosclerotic plaque,7 but not the native tyrosine-containing
peptide, was able to outcompete the binding of the
3-nitrotyrosine-coupled HRP bait to immunoglobulins. More-
over, the circulating immunoglobulins were able to recognize
nitrated fibrinogen and other nitrated plasma proteins but not
the native counterparts (Figure 3B). These data support a
possible specific antigenic role of those endogenous-nitrated
proteins as the neo-epitope that triggers antinitrotyrosine
immunoglobulins. It is remarkable that both of these proteins
(apoA-I and fibrinogen) have been reported previously to be
nitrated selectively in plasma from patients with CAD rela-
tive to healthy control subjects, and that nitration of these
particular proteins may have a potential functional role in
cardiovascular events. In the case of fibrinogen, nitration
increases the rate as well as the extent of fibrin clot forma-
tion,17,18 leading potentially to enhanced thrombotic risk and
adverse cardiovascular events. On the other hand,
3-nitrotyrosine-modified apoA-I was found in serum and
human atherosclerotic lesions. Furthermore, exposure of
apoA-I to myeloperoxidase, an enzymatic source of nitric
oxide-derived oxidants, creates a dysfunctional form of high-
density lipoprotein with diminished ATP-binding cassette
sub-family A1-dependent cholesterol efflux capacity and
reduced lecithin cholesterol acyl transferase activity.7,37 The
molecular mechanisms for the production of immunoglobu-
lins with specific and selective epitope recognition for
3-nitrotyrosine have been explored in mouse models.35,36
Termination of self-tolerance and escaping of negative selec-
tion after active immunization with nitrated peptides was
documented.35,38 Moreover, monoclonal antibodies that rec-
ognize only nitrated -synuclein (including stereospecific
clones that recognized 1 of the 4 nitrated tyrosine residues in
-synuclein) but not the unmodified protein or other tyrosine-
nitrated proteins,32 as well as antibodies recognizing only
nitrated Mn superoxide dismutase33 and only nitrated tau34
have been reported. In one model of mouse neurodegenera-
tion, the specific immune response to nitrated -synuclein
produced a vigorous immunoinflammatory response that led
to the degeneration of dopamine-producing neurons.39
The pathophysiological relevance of circulating immuno-
globulins targeting protein 3-nitrotyrosine remains to be
determined. Indeed, despite the strikingly elevated levels of
anti-3-nitrotyrosine antibodies in subjects with CAD, it is
possible that the antibody response within atherosclerotic
plaque may promote a protective role, with immunoglobulins
targeting proteins bearing potentially threatening modifica-
tions for destruction. Furthermore, the relatively high-risk
cohort of subjects examined (those undergoing elective diag-
nostic cardiac evaluations) makes the results of the current
study of unclear relevance when translated to a community-
based screen. It also remains to be determined whether
elevated levels of 3-nitrotyrosine-targeted antibodies are in-
creased in subjects prior to clinically overt development of
atherosclerotic CAD, and whether increased levels may serve
as a sentinel of increased risk of major adverse cardiac events.
Further studies are needed to both identify the role, if any, of
3-nitrotyrosine immunoglobulins in CAD pathophysiology,
as well as whether anti-3-nitrotyrosine immunoglobulin titer
carries prognostic value and is modulated by CAD-targeting
therapies.
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Affinity enrichment of nitrated proteins from human atherosclerotic lesions. Proteins extracted from atherosclerotic human lesions
(0.84 mg of protein) were incubated with Dyna‐beads/protein‐A cross‐linked to a polyclonal anti‐nitrotyrosine antibody in lysis buffer
(150 mM NaCl, 1.5 mM MgCl2, 2 mM Hepes, pH 7.4, 10% glycerol, 1% Triton X‐100, 1 mM PMSF, 1/100 Sigma protease inhibitor
without metal chelators). Enrichment using the same beads cross‐linked to a non‐specific IgG were used as control. Bound fractions
from the beads were eluted using 0.1 M citrate buffer, pH 2.5, and the fractions were separated in 10% SDS‐PAGE, transferred to PVDF
and probed with a polyclonal anti‐nitrotyrosine antibody. (A) Colloidal blue stain and (B) western blot developed with an anti‐
nitrotyrosine polyclonal antibody. Lanes: 1) Input un‐fractionated lesion protein extract; 2) Unbound fraction from the anti‐
nitrotyrosine antibody beads. 3) Bound fraction from the anti‐nitrotyrosine antibody beads; 4) Bound fraction from the non‐specific
IgG beads. Representative data from 3 different human lesions.
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Affinity enrichment for nitrated proteins from human CAD plasma. Pooled plasma CAD subjects was applied to a agarose column
that a polyclonal anti‐nitrotyrosine antibody was ligated. After binding and extensive washing the bound proteins were eluted with
0.1 M glycine, pH 2.5, containing 0.15 M NaCl and separated in 10% SDS‐PAGE. (A) Colloidal blue stain and (B) western blot
developed with an anti‐nitrotyrosine polyclonal antibody. Lanes 1, and 4, un‐fractionated plasma (input); Lanes 2, and 5, last wash
before elution; Lanes 3, and 6, eluted bound proteins.
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Supplementary Table 1.  Proteins that bound to anti‐nitrotyrosine antibodies in human 
atherosclerotic lesions. 
Protein  Uniprot 
Accession 
Number 
Molecular 
Weight 
(kDa) 
Unique 
peptides 
14‐3‐3 protein sigma   P31947  28  6 
14‐3‐3 protein zeta/delta   P63104  28  4 
78 kDa glucose‐regulated protein   P11021  72  6 
Actin‐related protein 2/3 complex subunit 4   P59998  20  3 
Adenylyl cyclase‐associated protein 1   Q01518  52  5 
Adipocyte plasma membrane‐associated protein   Q9HDC9  46  3 
ADP‐ribosylation factor 3   P61204 (+1)  21  3 
Alcohol dehydrogenase 1B   P00325  40  8 
Aldehyde dehydrogenase X, mitochondrial   P30837  57  3 
Aldehyde dehydrogenase, mitochondrial   P05091  56  5 
Alpha‐1‐acid glycoprotein 1   P02763  24  5 
Alpha‐1‐antichymotrypsin   P01011  48  9 
Alpha‐1‐antitrypsin   P01009  47  24 
Alpha‐1B‐glycoprotein   P04217  54  8 
Alpha‐2‐antiplasmin   P08697  55  4 
Alpha‐actinin‐1   P12814  103  23 
Alpha‐actinin‐4   O43707  105  39 
Alpha‐enolase   P06733  47  14 
Angiotensinogen   P01019  53  3 
Annexin A1   P04083  39  6 
Annexin A4   P09525  36  4 
Annexin A5   P08758  36  8 
Annexin A6   P08133  76  13 
Antithrombin‐III   P01008  53  9 
Apolipoprotein A‐I   P02647  31  13 
Apolipoprotein A‐IV   P06727  45  14 
Apolipoprotein D   P05090  21  8 
Apolipoprotein E   P02649  36  15 
Asporin   Q9BXN1  43  3 
ATP synthase subunit alpha, mitochondrial   P25705  60  10 
ATP synthase subunit beta, mitochondrial   P06576  57  15 
Basement membrane‐specific heparan sulfate proteoglycan 
core protein  
P98160  469  31 
Beta‐2‐glycoprotein 1   P02749  38  7 
C4b‐binding protein alpha chain   P04003  67  12 
Cadherin‐13   P55290  78  7 
Calmodulin‐like protein 5   Q9NZT1  16  4 
Calponin‐1   P51911  33  6 
Carbonic anhydrase 1   P00915  29  6 
Catalase   P04040  60  12 
Cathepsin D   P07339  45  6 
CD109 antigen   Q6YHK3  162  3 
CD5 antigen‐like   O43866  38  3 
Ceruloplasmin   P00450  122  13 
Chloride intracellular channel protein 1   O00299  27  3 
Clathrin heavy chain 1   Q00610  192  9 
Clusterin   P10909  52  16 
Coagulation factor X   P00742  55  3 
Cofilin‐1   P23528  19  5 
Collagen alpha‐1(VI) chain   P12109  109  14 
Collagen alpha‐1(XII) chain   Q99715  333  6 
Collagen alpha‐1(XIV) chain   Q05707  194  28 
Collagen alpha‐1(XV) chain   P39059  142  4 
Collagen alpha‐1(XVIII) chain   P39060  178  4 
Collagen alpha‐2(IV) chain   P08572  168  3 
Collagen alpha‐2(VI) chain 4  P12110  109  10 
Collagen alpha‐3(VI) chain   P12111  344  43 
Complement C1s subcomponent   P09871  77  4 
Complement C3   P01024  187  58 
Complement C4‐A   P0C0L4 (+1)  193  32 
Complement C5   P01031  188  24 
Complement component C6   P13671  105  8 
Complement component C7   P10643  94  6 
Complement component C8 gamma chain   P07360  22  3 
Complement component C9   P02748  63  15 
Complement factor B   P00751  86  8 
Complement factor H   P08603  139  29 
Complement factor H‐related protein 1   Q03591  38  3 
Cystatin‐B   P04080  11  3 
Cysteine and glycine‐rich protein 1   P21291  21  4 
Cytosol aminopeptidase   P28838  56  5 
Cytosolic non‐specific dipeptidase   Q96KP4  53  3 
Decorin   P07585  40  4 
Desmocollin‐3   Q14574  100  3 
Dihydropyrimidinase‐related protein 2   Q16555  62  4 
EGF‐containing fibulin‐like extracellular matrix protein 1   Q12805  55  9 
Elongation factor 1‐alpha 1   P68104 (+1)  50  5 
Elongation factor 2   P13639  95  5 
Endoplasmin   P14625  92  3 
Epiplakin   P58107  556  11 
Eukaryotic initiation factor 4A‐I   P60842  46  3 
Ferritin heavy chain   P02794  21  3 
Ferritin light chain   P02792  20  9 
Fibrillin‐1   P35555  312  5 
Fibrinogen alpha chain   P02671  95  13 
Fibrinogen beta chain   P02675  56  26 
Fibronectin   P02751  263  36 
Fibulin‐1   P23142  77  9 
Filamin‐A   P21333  281  57 
Fructose‐bisphosphate aldolase A   P04075  39  8 
Galectin‐1   P09382  15  3 
Galectin‐3   P17931  26  4 
Galectin‐3‐binding protein   Q08380  65  9 
Galectin‐7   P47929  15  7 
Gasdermin‐A   Q96QA5  49  5 
Gelsolin   P06396  86  17 
Glucose‐6‐phosphate isomerase   P06744  63  8 
Glutamate dehydrogenase 1, mitochondrial   P00367 (+1)  61  4 
Glutathione S‐transferase P   P09211  23  5 
Glycogen phosphorylase, brain form   P11216  97  6 
Guanine nucleotide‐binding protein G(i) subunit alpha‐2   P04899  40  3 
Haptoglobin   P00738  45  16 
Haptoglobin‐related protein   P00739  39  3 
Heat shock 70 kDa protein 1A/1B   P08107  70  6 
Heat shock cognate 71 kDa protein   P11142  71  13 
Heat shock protein beta‐1   P04792  23  7 
Hemoglobin subunit delta   P02042  16  3 
Hemopexin   P02790  52  11 
Heparin cofactor 2   P05546  57  3 
Histidine ammonia‐lyase   P42357  73  4 
Histone H2A type 1   P0C0S8 (+5)  14  4 
Histone H4   P62805  11  5 
HLA class II histocompatibility antigen, DR alpha chain   P01903  29  3 
Ig gamma‐2 chain C region   P01859  36  6 
Ig gamma‐3 chain C region   P01860  41  6 
Ig heavy chain V‐III region BUT   P01767  12  4 
Ig heavy chain V‐III region GAL   P01781  13  6 
Ig heavy chain V‐III region TEI   P01777  13  3 
Ig heavy chain V‐III region VH26   P01764  13  3 
Ig kappa chain V‐I region AU   P01594  12  3 
Ig kappa chain V‐III region SIE   P01620 (+3)  12  3 
Ig kappa chain V‐IV region Len   P01625 (+3)  13  3 
Ig lambda chain V‐III region LOI   P80748  12  3 
IgGFc‐binding protein   Q9Y6R7  572  13 
Immunoglobulin lambda‐like polypeptide 5   B9A064  23  5 
Integrin alpha‐1   P56199  131  3 
Integrin alpha‐V   P06756  116  5 
Integrin beta‐1   P05556  88  11 
Integrin beta‐2   P05107  85  3 
Inter‐alpha‐trypsin inhibitor heavy chain H1   P19827  101  6 
Inter‐alpha‐trypsin inhibitor heavy chain H2   P19823  106  6 
Inter‐alpha‐trypsin inhibitor heavy chain H4   Q14624  103  4 
Interleukin‐36 gamma   Q9NZH8  19  3 
Involucrin   P07476  68  4 
Kallistatin   P29622  49  4 
Kininogen‐1   P01042  72  4 
Lactadherin   Q08431  43  16 
Leukotriene A‐4 hydrolase   P09960  69  4 
Lipopolysaccharide‐binding protein   P18428  53  4 
Liver carboxylesterase 1   P23141  63  4 
L‐lactate dehydrogenase A chain   P00338  37  7 
L‐lactate dehydrogenase B chain   P07195  37  6 
Lumican   P51884  38  10 
Lysosome‐associated membrane glycoprotein 1   P11279  45  4 
Lysosome‐associated membrane glycoprotein 2   P13473  45  3 
Macrophage‐capping protein   P40121  38  4 
Major vault protein   Q14764  99  5 
Malate dehydrogenase, cytoplasmic   P40925  36  3 
Malate dehydrogenase, mitochondrial   P40926  36  3 
Membrane primary amine oxidase   Q16853  85  9 
Mimecan   P20774  34  5 
Myoferlin   Q9NZM1  235  4 
Myosin light polypeptide 6   P60660  17  6 
Myosin‐10   P35580  229  9 
Myosin‐11   P35749  227  24 
Myosin‐9   P35579  227  15 
Neuroblast differentiation‐associated protein AHNAK   Q09666  629  3 
Peptidyl‐prolyl cis‐trans isomerase A   P62937  18  8 
Periostin   Q15063  93  20 
Peroxiredoxin‐2   P32119  22  4 
Peroxiredoxin‐6   P30041  25  3 
Phosphatidylinositol‐glycan‐specific phospholipase D   P80108  92  4 
Phosphoglucomutase‐1   P36871  61  4 
Phosphoglucomutase‐like protein 5   Q15124  62  14 
Phosphoglycerate kinase 1   P00558  45  11 
Phosphoglycerate mutase 1   P18669  29  4 
Phospholipid transfer protein   P55058  55  10 
Pigment epithelium‐derived factor   P36955  46  5 
Plasma protease C1 inhibitor   P05155  55  9 
Plasminogen   P00747  91  6 
Plastin‐2   P13796  70  24 
Plastin‐3   P13797  71  16 
Polymerase I and transcript release factor   Q6NZI2  43  3 
Polyubiquitin‐B   P0CG47 (+3)  26  3 
Profilin‐1   P07737  15  6 
Prostacyclin synthase   Q16647  57  5 
Protein disulfide‐isomerase A3   P30101  57  5 
Protein disulfide‐isomerase   P07237  57  5 
Protein POF1B   Q8WVV4  68  4 
Protein S100‐A7   P31151  11  8 
Protein S100‐A8   P05109  11  5 
Protein S100‐A9   P06702  13  9 
Prothrombin   P00734  70  4 
Pyruvate kinase isozymes M1/M2   P14618  58  25 
Rab GDP dissociation inhibitor beta   P50395  51  5 
Ras GTPase‐activating‐like protein IQGAP1   P46940  189  5 
Ras‐related protein Rab‐1A   P62820 (+2)  23  7 
Ras‐related protein Rab‐7a   P51149  23  4 
Rho GTPase‐activating protein 1   Q07960  50  3 
Serine protease HTRA1   Q92743  51  4 
Serotransferrin   P02787  77  35 
Serpin B3   P29508  45  16 
Serpin B4   P48594  45  5 
Serpin B5   P36952  42  3 
Serum paraoxonase/arylesterase 1   P27169  40  3 
SH3 domain‐binding glutamic acid‐rich‐like protein   O75368  13  4 
Synaptic vesicle membrane protein VAT‐1 homolog   Q99536  42  3 
Tenascin   P24821  241  8 
Tetranectin   P05452  23  3 
Thioredoxin domain‐containing protein 5   Q8NBS9  48  4 
Thrombospondin‐1   P07996  129  4 
Thrombospondin‐2   P35442  130  9 
Thymidine phosphorylase   P19971  50  5 
Transforming growth factor‐beta‐induced protein ig‐h3   Q15582  75  9 
Transgelin   Q01995  23  17 
Transgelin‐2   P37802  22  9 
Transketolase   P29401  68  8 
Transmembrane protein 43   Q9BTV4  45  3 
Transthyretin   P02766  16  7 
Triosephosphate isomerase   P60174  27  8 
 
Sequence‐to‐spectrum assignments from three biological replicates were combined in Scaffold.  The 
proteins listed above satisfied two criteria: (1) identified by at least one protein capture method (≥3 
unique peptides), (2) not identified in the respective non‐specific IgG column.  Uniprot accession 
numbers correspond to the full‐length unprocessed precursor when available (www.uniprot.org).  
Additional accessions were listed if the observed peptides could not distinguish between protein 
isoforms.  Proteins were identified in three independent human lesion extracts analyzed at different 
times by LC‐MS/MS as described in the Methods section. 
Tropomyosin alpha‐1 chain   P09493  33  3 
Tropomyosin beta chain   P07951  33  7 
Tubulin alpha‐1B chain   P68363 (+1)  50  9 
Tubulin beta‐2C chain   P68371  50  13 
Tubulointerstitial nephritis antigen‐like   Q9GZM7  52  3 
Vimentin   P08670  54  31 
Vinculin   P18206  124  33 
Vitamin D‐binding protein   P02774  53  6 
Vitamin K‐dependent protein S   P07225  75  5 
WD repeat‐containing protein 1   O75083  66  6 
Zinc‐alpha‐2‐glycoprotein   P25311  34  6 
Supplementary Table 2. Nitrated proteins and the corresponding modified peptides in human CAD 
plasma. 
Protein  Accession  Sequence 
Ig gamma‐1 chain C region   P01857  (K)FNWY161*VDGVEVHNAK(T)
(K)TTPPVLDSDGSFFLY290*SK(L)
Ig kappa chain C region  P01834  (K)SGTASVVCLLNNFY32*PR(E)
(K)VY84*ACEVTHQGLSSPVTK(S)
Ig lambda chain C region  P01842  (R)SY84*SCQVTHEGSTVEK(T)
Ig mu chain C region  P01871  (K)GVALHRPDVY332*LLPPAR(E)
Ig alpha‐1 chain C region  P01876  (K)Y276*LTWASRQEPSQGTTTFAVTSILR(V)
Ig heavy chain V‐III region WEA  P01763  (K)NSLY80*LQMSSLR(A)
Ig heavy chain V‐III region BUR  P01773  (R)TEDTAVYY95*CAK(L)
Ig kappa chain V‐III region B6  P01619  (R)ASQSLSGNY33*LAWYQQKPGQAPR(L)
Zinc finger and BTB domain‐containing 
protein 1 
Q9Y2K1  (K)ISAECFDLILQFM(OH)Y83*L(G)
Protein EFR3 homolog B  Q9Y2G0  (S)KISEVLGGSGY669*NSDR(L)
Accession: Uniprot accession, which refers to the unprocessed precursor protein when available 
(www.uniprot.org).  *Residue refers to the identified 3‐nitrotyrosine residue.  Amino acid 
modifications are designated as, M(OH), methionine oxidation (+16 amu) and Y*, tyrosine nitration 
(+45 amu).  Putative Sequest peptide assignments containing 3‐nitrotyrosine were accepted only if 
the following multiple selection criteria were met: (1) Peptide assignments contained a Tyr residue 
with +45 amu mass increase in the y‐ or b‐ion series. (2) Manual inspection of the MS/MS spectra for 
a continuous b‐ or y‐ion series of at least 5 fragment ions and assignment of the most intense 
fragment peaks to a b‐ or y‐ion, a b‐ or y‐ion resulting from a neutral loss of water/ammonia, or a 
multiply protonated fragment ion.  These sites of tyrosine nitration were identified in two 
independent pooled CAD plasma analyzed at different times by LC‐MS/MS as described in the 
Methods section.  
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